It is worth noting that, in current clinical practice, international guidelines recommend a rational use of NGS in advanced breast cancer, prioritizing targeted testing for known actionable mutations (e.g., PIK3CA, BRCA1/2, ESR1, etc.). The gene discussed is ESR1; the disease is breast carcinoma.